INTRODUCTION
Prostate cancer (PC) is the second most widespread malignancy and the second leading cause of cancer-related deaths among men in many western countries including USA. Clinically, PC is generally diagnosed in men over 50 years of age; with increasing life expectancy the prevalence of PC is likely to increase worldwide [1, 2] . For PC chemoprevention at the present time there is considerable emphasis in identifying novel botanicals that selectively induce apoptosis and growth arrest of PC cells without producing cytotoxic effects on normal cells. Because of inadequate treatment options available for prostate cancer, there is an urgent requirement for developing innovative preventive approaches for this malignancy. For a variety of reasons naturally occurring plant compounds and dietary substances are attaining increasing response as cancer chemopreventive agents [3] [4] [5] [6] [7] . The majority of anticancer drugs are natural products or their derivatives. More than 200 drugs derived from natural products are in preclinical or clinical development and evaluation [8, 9] .
J. regia belongs to the family Juglandaceae which includes 3 species: J. nigra, J. cinerea, and J. regia. Juglans regia L. commonly known as walnut tree is a well-known member of Juglans genus, constituting an important species of deciduous trees found primarily in temperate areas. J. regia extract contains ellagitannins which contains anti-cancer agent and with antiinflammatory properties. The key chemical composition of walnut is juglone (5-hydroxy-1, 4-naphthoquinone), the toxic compound which is found only in green and fresh walnuts, but such property disappear in dried leaves. Other several phenolic compounds with antioxidant properties have been identified in J. regia leaves [10] [11] [12] [13] . Walnut leaves are considered a source of healthcare compounds, and have been extensively used in traditional medicine for treatment of skin inflammations, hyperhidrosis and ulcers and for its anti-diarrheal, antihelmintic, antiseptic and astringent properties [12] [13] [14] .
The objective of the present study was to evaluate the anti-proliferative activity of the hexane extract of the leaves of Juglans regia against human prostate (PC3) cancer cells in vitro. We also studied the effect of the extract on cell cycle phase distribution as well as on the apoptosis induction using flow cytometry and inverted phase contrast microscopy.
EXPERIMENTAL Plant material and extraction procedure
Juglans regia leaves were collected during JulyAugust 2013 from a local site in Jianguo District, China. The plant material was identified by Professor Long Yuan-xi of the Huazhong Agricultural University, Wuhan, and a voucher specimen (no. DFST/HAU-0097654) was submitted to the University Herbarium. The plant material was confirmed by a well-known taxonomist. The leaves were thoroughly washed with tap water, shade-dried and then chopped into small pieces. Hexane (95 %) was used for hot extraction which was carried out for 4 h using 
Chemicals and reagents
Growth medium RPMI-1640 (Hangzhou Sijiqing Biological Products Co., Ltd, China), Minimum Essential Medium (MEM), Fetal Calf Serum (GIBCO), trypsin, penicillin, MTT, streptomycin, DMSO and phosphate buffer saline (PBS) were used in this study. MTT kit was obtained from Roche (USA). Annexin V-FITC-Propidium Iodide Apoptosis Detection Kit was purchased from Sigma (USA). All other chemicals and solvents used were of the highest purity grade. Cell culture plastic ware was bought from BD Falcon (USA).
Cell lines and cell viability assay
Human prostate carcinoma (PC3) cells were procured from the Shanghai Institute of Cell Resource Center of Life Science (Shanghai, China). All the cells were grown in a humidified 5 % CO 2 atmosphere at 37 o C in an incubator, and cultured in RPMI-1640 medium supplemented with 10 % heat-inactivated newborn calf serum, 100 IU/ml penicillin and 100μg/mL streptomycin. Inhibition of cell proliferation of the extract was measured by the MTT assay. Briefly, PC3 cells were plated in 96-well culture plates (1 × 10 5 cells/well) separately. After 24 h incubation, cells were treated with Juglans regia extract (5, 25, 50, 75 and 100 μg/mL; eight wells per concentration) for 24 h; MTT solution (5 mg/mL) was then added to each well. After 4 h incubation, the formazan precipitate was dissolved in dimethyl sulfoxide (100 μL) and then the absorbance was measured in an ELISA reader (Thermo Molecular Devices Co., Union City, USA) at 570 nm. Cell viability ratio was calculated as in Eq 1.
Cell viability (%) = {(Ac -At)/Ac}100 ………. (1) where Ac and At are the absorbance of control and treated cells, respectively.
Cytotoxicity was expressed as the concentration of the extract inhibiting cell growth by 50 % (IC 50 value).
Cell cycle phase distribution analysis by flow cytometry
Human prostate carcinoma PC3 cells (1 × 10 6 ) were seeded in 60-mm dishes and subjected to various concentrations (5, 25, 50, 75 and 100 μg/mL) of the Juglans regia extract for 48 h. Floating and adherent cells were collected by trypsinization and washed twice with PBS. Cells were incubated in 70 % ethanol at -20 °C overnight, treated with 10 µg/mL RNase A, then stained with 2.0 µg/mL of propidium iodide. Finally the stained cells were analyzed and studied by flow cytometry at wavelength of 488 nm (FACS Calibur instrument (BD Biosciences, San Jose, CA, USA) equipped with Cell Quest 3.3 software).
Annexin V binding assay
We performed annexin V binding assay using flow cytometry to confirm apoptosis. The PC3 cells were treated with Juglans regia extract (5, 25, 50, 75 and 100 μg/mL) for 48 h. Subsequently, treated and untreated cells were harvested by trypsinization. Harvested cells were then incubated in annexin V-FITC (50 ng/mL) and propidium iodide (20 µg/mL), at room temperature for 30 min in the dark, and analysed using a FACS Calibur flow cytometer (BD Bioscience) taking a minimum 25,000 cells in each sample.
Live cell morphology assay of apoptosis
Apoptotic morphological characteristics of human prostate carcinoma cells were recorded with an inverted phase contrast microscope (IPCM) (Olympus, Japan) after treatment with various concentrations (5, 25, 50, 75 and 100 μg/mL) of the extract. Cells cultured with 0.5 % DMSO were used as the control.
Statistical analysis
All the data were analysed using analysis of variance (ANOVA), followed by Dunnett's test for pair-wise comparison. Mean values are presented with their standard deviation (SD). Statistical significance was defined as p < 0.05 for all tests.
RESULTS

Anti-proliferative activity of Juglans regia extract
Juglans regia leaf extract was evaluated for antiproliferative activity using the MTT assay against the human prostate carcinoma (PC3) cells for 24 h (Figure 1) . The extract exhibited potent and dose-dependent cytotoxic activity against these cancer cells. The IC 50 value of the extract was calculated to be 48.4 µg/mL. IC 50 value gives an indication of the potency of a drug/agent. As shown in Figure 1 , 100 µg/mL extract exhibited a very strong anticancer effect at which approximately only 15 % of the cells were alive and 85 % cells were damaged.
Effect of Juglans regia extract on cell cycle phase distribution
Treatment with different concentrations of the extract for 48 h induced an increase in the population of cells in the sub-G1 phase and a slight decrease in the G2/M phase ( Figure 2 ). 
Quantification of apoptotic cell death induced by Juglans regia extract
To verify if this increase in the sub-G1 population of human prostate cancer cells was due to apoptosis, PC3 cells were labeled with FITCconjugated Annexin V and PI for flow cytometry analysis. The results of the flow cytometry study with Annexin V/FITC and PI showed that, within 48 h of incubation, approximately 9.5 %, 15.5 % and 26.3 % of the cells underwent early apoptosis after treatment with 5, 50 and 100 µg/mL of the extract respectively. Similarly, 5.2 %, 11.2 % and 18.9 % of the cells underwent late apoptosis after treatment with 5, 50 and 100 µg/mL of the extract respectively ( Figure 3 and Figure 4 ).
Apoptosis induced by Juglans regia extract
The induction of apoptosis by Juglans regia extract was confirmed by studying apoptotic body formation using inverted phase contrast microscope. As shown in Figure 5 , the formation of apoptotic bodies was observed 48 h posttreatment in Juglans regia extract-treated cells. The extract exhibited a dose-dependent effect on PC3 cells. 
DISCUSSION
Prostate cancer (PC) is the second most widespread malignancy and the second leading cause of cancer-related deaths among men in many Western countries including USA [1] . Clinically, PC is generally diagnosed in men over 50 years of age; with increasing life expectancy the prevalence of PC is likely to increase worldwide. PC usually develops from androgendependent to androgen-independent stage, making anti-androgen therapy unproductive, thus leading to a rise in metastatic potential [1, 15] . Suppression of cancer development frequently involves modulation of signal transduction pathways, resulting in alterations in gene expression, arrest in cell cycle progression or apoptosis. Apoptotic cell death represents a universal and intricately efficient suicide pathway, considered as a perfect method for elimination of damaged cells [16] . Recently, the apoptosis signaling systems have been shown to provide encouraging targets for the development of novel anticancer agents [17] . Several plant-derived bioactive compounds are known to be chemopreventive agents inducing apoptosis in a number of experimental models of carcinogenesis. Thus induction of apoptosis is considered as a possible mechanism of chemo preventive agents [18] [19] [20] .
In this study, the Juglans regia hexane extract was evaluated for its anticancer activity against human prostate PC3 cancer cells. The extract showed a dose-dependent inhibition of the cancer cells with 100 µg/mL of the extract producing the most potent growth inhibition. In order to further study the mechanism of the extract, we evaluated effect of the extract on cell cycle analysis, apoptosis induction using Annexin V binding assay as well as inverted phase contrast microscopy. The results revealed that the Juglans regia extract increased the fraction of sub-G1 cells in a dose-dependent manner along with a slight decrease in G2/M fraction of cells. The apoptosis assay revealed that the number of cells with both late and early apoptosis increases greatly and dose-dependently after extract treatment.
CONCLUSION
Juglans regia leaf extract induces potent growth inhibitory effects against human prostate cancer cells (PC3) by inducing apoptosis and by altering the cell cycle phase distribution in these cells. Therefore, the extract may find application in curbing prostate cancer and is a potential complementary and alternative medicinal treatment for this disease.
